Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 11.55 USD -2.28% Market Closed
Market Cap: 2.5B USD

EV/EBITDA
Enterprise Value to EBITDA

-8.9
Current
-9.4
Median
13
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-8.9
=
Enterprise Value
2.2B USD
/
EBITDA
-246.8m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
Ocular Therapeutix Inc
NASDAQ:OCUL
Average EV/EBITDA: 439.7
Negative Multiple: -8.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
CH
Novartis AG
SIX:NOVN
11.6
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-8
2-Years Forward
EV/EBITDA
1.4
3-Years Forward
EV/EBITDA
-15.4